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Abstract
Background
Laboratory diagnosis of chronic Chagas disease is a troubling factor due to lack of reference
tests. The WHO suggests the use of two distinct commercial serological tests in parallel.
The performance of commercial immunoassays might fluctuate depending on the antigenic
matrices and the local strains of T. cruzi in different geographical settings. The use of anti-
genic matrices based on chimeric proteins can solve these limitations. Here, we evaluated
the diagnostic performance of two chimeric T. cruzi antigens (IBMP-8.1 and -8.4) to diag-
nose chronic Chagas disease in individuals from endemic South American countries.
Methodology/Principal findings
IBMP-8.1 and IBMP-8.4 chimeric antigens were expressed as soluble proteins in E. coli and
purified using chromatography methods. Reactivity of IBMP-8.1 and IBMP-8.4 was
assessed using an in-house ELISA with sera from 122 non-infected and 215 T. cruzi-
infected individuals from Argentina, Bolivia, and Paraguay. Cut-off values were based on
ROC curves and performance parameters were determined using a dichotomous approach.
Area under the curve values were > 99.7% for both IBMP-8.1 and IBMP-8.4 antigens. IgG
levels in T. cruzi-positive and negative samples were higher for IBMP-8.4 than IBMP-8.1.
Both IBMP-8.1 and -8.4 were 100% specific, while IBMP-8.4 were 100% sensitive com-
pared to IBMP-8.1 (95.3%). Admitting RI values of 1.0 ± 0.10 as the inconclusive interval,
6.2% of the samples tested using IBMP-8.1 and 2.1% using IBMP-8.4 fell inside the grey
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zone. Based on accuracy and diagnostic odds ratio values, IBMP-8.4 presented the best
performance. Differences in sensitivity and IgG levels among the samples from Argentina,
Bolivia, and Paraguay were not significant.
Conclusions/Significance
Our findings showed a notable performance of IBMP-8.1 and -8.4 chimeric antigens in diag-
nosing chronic Chagas disease in individuals from endemic South American countries, con-
firming our hypothesis that these antigens could be used in geographical areas where
distinct T. cruzi DTUs occur.
Introduction
Chagas’ disease (CD) is a life-threating zoonosis caused by the hemoflagellate protozoan Try-
panosoma cruzi. The parasite is transmitted by contact with dejections of infected blood-suck-
ing triatomine bugs, by tissue and organ transplantation, consumption of parasite-
contaminated food or beverages, blood transfusion, and from mother-to-child during preg-
nancy [1]. Although T. cruzi was discovered over a century ago, it is still posing a substantial
public health threat, bearing in mind that the vast majority of the affected individuals lack
access to treatment and diagnosis. As a matter of fact, CD is considered an essential neglected
disease in the Americas [2].
Laboratory diagnosis of the disease is a troubling factor because the reference test is based
on direct visualization of motile trypomastigotes in a blood smear, restricting the useful win-
dow of the reference test to the first 4–8 weeks post-exposure, during the acute phase. Because
of the low and intermittent parasitemia, the majority of CD diagnosis is performed during the
chronic phase, employing immunoassays for indirect detection of specific anti-T. cruzi anti-
bodies. Most immunoassays are based on antigenic matrices with particular T. cruzi amino
acid sequences meant to bind to their complementary anti-T. cruzi antibodies [3]. Due to their
simplicity, low cost, and efficiency, antibody-based assays are the diagnostic methods of choice
in chronic CD. However, due in part to the substantial genetic variability of the pathogen, the
performance of commercial immunoassays might fluctuate depending on the local strains of
T. cruzi and the employed antigenic matrices in different geographical regions [4].
The use of antigenic matrices based on chimeric proteins can solve these limitations.
Indeed, chimeras are composed of repetitive and conserved immunodominant amino acid
fragments of several T. cruzi-proteins. Accordingly, the possibility of a false-negative result
decreases due to the availability of several distinct epitopes to be recognized by specific anti-T.
cruzi antibodies, despite the antigenic variability across T. cruzi DTUs. Owing to the increase
of migration and shifts worldwide, gradually favoring the spreading of infected people in non-
endemic areas and transforming the disease into a global health alarm [5–7], the development
of new serological tests should be prioritized, mainly in North America, Europe, and Oceania
countries. Recently, our group synthesized and investigated the performance of four chimeric
proteins (IBMP-8.1, -8.2, -8.3, and -8.4) in detecting antibodies against T. cruzi in human
serum [8–10]. We observed that the chimeric antigens maintained their performance despite
the antigenic variability across Brazilian T. cruzi strains. In fact, samples from endemic (Bahia,
Goia´s, Minas Gerais, and Pernambuco States) and non-endemic Brazilian settings (Parana´
State) were assayed, and the chimeras, mainly IBMP-8.1 and IBMP-8.4, rendered high accu-
racy values. Similar results were found when an international commercial panel composed of
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samples from the USA, Nicaragua, Mexico, and Argentina was also assayed, suggesting that
the chimeras could be able to identify T. cruzi-positive individuals regardless their geographi-
cal origin [9]. To confirm our hypothesis, we evaluated the performance of IBMP-8.1 and
IBMP-8.4 chimeras to diagnose Chagas disease in individuals from endemic South American
countries. In this study, we preferred to assess the IBMP-8.1 and -8.4 antigens, because they
had previously shown the highest performance values, among the evaluated antigens.
Materials and methods
Ethical statements
This investigation followed the tenets of the Declaration of Helsinki and Guidelines according
to Resolution N˚1480/11 of the “Ministerio de Salud” from Argentina and were approved by
the Local Medical Ethics Committees named “Comite´ del Instituto Regional de Medicina de la
Universidad Nacional del Nordeste (UNNE)”, Resistencia, Chaco; “IDACH (Chaco Aboriginal
Institute)”; “Comite´ de E´tica de Investigacio´n en Salud (CIEIS)” y “Comite´ de E´tica del Hospi-
tal Zonal de Añatuya", Añatuya, Santiago del Estero; and Committees of Ramos Mejı´a and Pir-
ovano Hospitals from Buenos Aires. We employed samples from the biorepository of the
Laboratory of Molecular Biology of Chagas Disease (Institute for Research on Genetic Engi-
neering and Molecular Biology—INGEBI CONICET-UBA). In order to maintain confidenti-
ality over patient information, the samples were anonymized so that the researchers do not
have access to patient’s individual information avoiding the need for verbal or written consent.
Recombinant chimeric protein acquisition
IBMP-8.1 and IBMP-8.4 were expressed as soluble proteins in Escherichia coli-Star (DE3) cells
grown in Luria-Bertani medium supplemented with 0.5 mM isopropyl-β-D-1-thiogalactopyra-
noside (IPTG). Proteins were purified by both affinity and ion exchange chromatography,
then quantified using a fluorometric assay. Plasmidial construct has already been described in
Santos et al. [8].
Clinical specimens
We used anonymized human sera obtained from INGEBI-CONICET serum bank, Buenos
Aires, Argentina. Based on an expected error of 2%, sensitivity and specificity of 99% and a
95% confidence interval, the minimum sample was 96 sera from non-infected and 96 from T.
cruzi-infected individuals. We included sera from 122 non-infected and 215 T. cruzi-infected
individuals from rural endemic localities from 13 Argentine Provinces (Catamarca, Chaco,
Cordoba, Corrientes, Entre Rios, Formosa, Jujuy, Misiones, Salta, San Juan, San Luis, Santiago
del Estero, and Tucuman), from 6 Bolivian Departments (Chuquisaca, Cochabamba, Oruro,
Potosı´, Santa Cruz de la Sierra, and Tarija), and from three Departments in Paraguay (Amam-
bay, Cordillera, and Paraguarı´). Information about the city of origin was recovered only for
some samples, such as those from Formosa, Chaco, Santiago del Estero, Chuquisaca, Cocha-
bamba, Potosı´, Santa Cruz de la Sierra, Tarija, Amambay, and Ybytymı´. All other patients are
from several localities in Bolivia, Paraguay, and Argentina and reside in Buenos Aires for med-
ical attendance (Fig 1). The selection of clinical samples was based on positivity and negativity
by two commercial serological tests (ELISA and/or indirect hemagglutination assays), accord-
ing to World Health Organization advice [11]. Samples judged as inconclusive, or those that
returned discordant results, were excluded. Each sample was assumed an identifier code in the
laboratory to guarantee a blinded analysis. Digital map was obtained from the Brazilian Insti-
tute of Geography and Statistics (IBGE) cartographic database in shapefile (.shp), which was
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subsequently reformatted and analyzed using TerraView version 4.2, open source software
freely available from the National Institute for Space Research (www.dpi.inpe.br/terraview).
ELISA
Anti-T. cruzi serology was performed by ELISA according to previous reports [8,9]. Optical
density was determined in a VersaMax microplate reader using a filter of 450 nm (Molecular
Devices, San Jose, USA) and background values were subtracted from the measurement tests.
Data analysis
Data were encoded and analyzed using computer graphic software (GraphPad Prism version
7, San Diego, USA). Descriptive statistics were presented as geometric mean ± SD. Shapiro-
Wilk test followed by Student’s t-test was used to the normality of datasets, and when the vari-
ance homogeneity assumption was not confirmed, the Wilcoxon signed-ranks test was used.
All analyses were two-tailed and a p-value below 5% was considered significant (p< 0.05).
Cut-off point analysis was used to identify the optimal value of OD that differentiates negative
from positive samples. The threshold was defined by the largest distance from the diagonal
line of the receiver operating characteristic curve (ROC). The results were expressed by plot-
ting as an index that represents the ratio between the OD of the samples and the OD of the
cut-off. This index is referred to as reactivity index (RI) and all results< 1.00 were considered
negative. Samples were deemed inconclusive (or in grey zone) if the RI values fell into the
undetermined zone, which was hypothesized as RI values of 1.0 ± 10%. ELISA performance
was assessed using a dichotomous approach and compared with respect to sensitivity (Sen),
specificity (Spe), accuracy (Acc), likelihood ratios (LR), and the diagnostic odds ratio (DOR).
A flowchart (Fig 2) and a checklist (S1 Table) have been provided according to the Standards
for Reporting of Diagnostic Accuracy Studies (STARD) guidelines [12].
Results
The reactivity index (RI) distributions and assay performance parameters obtained for IBMP-
8.1 and IBMP-8.4 chimeras are illustrated in Fig 3 (individual data points are available in the
S2 Table). ROC curves were generated from 122 non-infected and 215 T. cruzi-infected indi-
viduals assayed by ELISA. Area under the curve (AUC) values were> 99.7%, demonstrating
high overall diagnostic accuracy. IgG levels in T. cruzi-positive samples were variable, ranging
from 1.64 for IBMP-8.1 to 1.84 for IBMP-8.4. For the panel of T. cruzi-positive samples,
IBMP-8.4 chimera produced the highest sensitivity (100%). IBMP-8.1 showed 95.3% sensitiv-
ity with 10 cases classified as false-negatives. The differences between these values were statisti-
cally significant. Nonetheless, this difference was almost negligible, considering that the 95%
CI values practically overlapped. Conversely, no false-positive results were obtained when T.
cruzi-negative samples were assayed with IBMP-8.1 and IBMP-8.4, resulting in a specificity
score of 100%.
Admitting RI values of 1.0 ± 0.10 as the inconclusive interval, we observed that four differ-
ent samples (3.3%) and one (0.8%) T. cruzi-negative sample fell inside the grey zone employing
IBMP-8.1 and IBMP-8.4 chimeras, respectively. Regarding T. cruzi-positive samples, we
observed the following number of samples in the inconclusive interval: 17 (7.9%) assayed with
Fig 1. Geographical distribution in Argentina, Bolivia, and Paraguay of the samples. Samples were collected from both T. cruzi-endemic and non-
endemic areas. The asterisk denotes the samples that were obtained in Buenos Aires health centers (the General Acute’s Hospital Dr. Ignacio Pirovano
and General Acute’s Hospital JM Ramos Mejı´a) from patients who were born in the indicated endemic areas.
https://doi.org/10.1371/journal.pone.0215623.g001
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IBMP-8.1 and 6 (2.8%) with IBMP-8.4. Overall analysis showed that 6.2% of the samples tested
using IBMP-8.1 and 2.1% using IBMP-8.4 showed RI values falling in the grey zone (Fig 3). Of
these, only four positive samples fell concomitantly inside the grey zone for IBMP-8.1 and
IBMP8.4 chimeras.
IBMP-8.4 was found to most accurately diagnose Chagas disease (100%), followed by
IBMP-8.1 (97.0%). Despite the statistical difference between these values, the 95% CI values
practically overlapped. The test performance was summarized by the diagnostic odds ratio
(DOR) value, which reached 24,947 for IBMP-8.1 (Fig 3). The IBMP-8.4 antigen showed an
Fig 2. Flowchart depicting study design in conformity with the Standards for Reporting of Diagnostic Accuracy Studies (STARD)
guidelines.
https://doi.org/10.1371/journal.pone.0215623.g002
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estimated DOR of 2,442.103. Between the chimeric proteins tested, IBMP-8.4 presented the
best performance, especially regarding its extremely high diagnostic odds ratio and AUC
value.
Fig 3. Reactivity index and performance parameters obtained with serum samples from T. cruzi-infected (POS) and non-infected (NEG) individuals. The
cut-off value is reactivity index = 1.0 and the shadowed area represents the grey zone (RI = 1.0 ± 0.10). Horizontal lines and numbers for each group of results
represent the geometric means (± 95% CI). AUC (Area Under Curve); Sen (Sensitivity); Spe (Specificity); Acc (Accuracy); LR (Likelihood Ratio); DOR
(Diagnostic Odds Ratio).
https://doi.org/10.1371/journal.pone.0215623.g003
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In order to evaluate the heterogeneity of recognition of IBMP-8.1 and IBMP-8.4 chimeras
by anti-T. cruzi specific antibodies due to the expected regional genetic variability of parasite
strains, RI and sensitivity values were compared using samples from T. cruzi-infected individ-
uals residing in Argentina (n = 133), Bolivia (n = 56), and Paraguay (n = 5). We excluded 21 T.
cruzi-positive samples from Buenos Aires city, not endemic for Chagas disease, due to the lack
of information regarding the geographical precedence of the corresponding patients. Differ-
ences in sensitivity and RI signal among all geographical areas are not statistically significant
(Fig 4; individual data points are available in the S3 Table).
Discussion
The high genetic and phenotypic intraspecific diversity of T. cruzi is extensively recognized
[13]; as it has been demonstrated using different biochemical, immunological and molecular
markers [14,15]. Homologous pairs of chromosomes can vary in number and sizes between
strains, as well as sequences and copy numbers of many genes, resulting in great genome plas-
ticity [16]. Accordingly, the parasite has been grouped into seven evolutionary discrete typing
units (DTUs) termed TcI–TcVI and Tcbat, with sub-classifications for regional strains in
clonets and clones [4,17]. Regional parasite genetic variations have substantial implications in
several features, such as epidemiological surveys [18], treatment response of T. cruzi-infected
individuals [19], development of vaccines and drugs [20], prevalence of clinical forms and
severity of manifestations [21,22], and even diagnosis [23]. Therefore, no single immunologi-
cal test has sufficient performance to be used alone. In this way, we emphasize the need for the
development of a diagnostic test able to identify chronic CD regardless of parasite genetic
diversity. Here, two T. cruzi chimeric antigens were assayed with serum samples from patients
Fig 4. Reactivity Index for performance by country origin assessment. The cut-off value is reactivity index = 1.0 and the shadowed area represents the grey
zone (RI = 1.0 ± 0.10). Horizontal lines and numbers for each group of results represent the geometric means (± 95% CI). RI (reactivity index); Sen
(sensitivity); CI (confidence interval).
https://doi.org/10.1371/journal.pone.0215623.g004
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residing in three endemic Latin America countries and returned accuracy values higher than
97%. The assays revealed a high diagnostic value. Indeed, the AUC values were greater than
99.7%, thereby showing an optimal discriminative power between chronic CD-positive and
negative samples. These data are similar to previous results found by our group when samples
from both Chagas disease endemic and non-endemic Brazilian settings were assayed either by
ELISA [9] and liquid microarray tests [10].
The diagnostic sensitivity was lower for IBMP-8.1 compared to IBMP-8.4, with statistically
significant differences between them. This difference is likely related to the antigenic composi-
tion of chimeras and genetic diversity of T. cruzi. In fact, IBMP-8.4 offers a vaster repertoire of
epitopes compared to IBMP-8.1. Of note, IBMP-8.1 is composed of conserved and repetitive
amino acid sequences of only three T. cruzi proteins (trans-sialidase, 60S ribosomal protein,
and surface antigen 2) while IBMP-8.4 comprising epitopes from seven T. cruzi proteins
(shed-acute-phase antigen, kinetoplastid membrane protein 11, trans-sialidase, flagellar repeti-
tive antigen protein, surface antigen 2, 60S ribosomal protein, and microtubule-associated pro-
tein). According to previous studies performed in Brazil, a country where DTU TcII is
predominant [4], the sensitivity displayed values higher than 97.4% and 99.1% for IBMP-8.1
and IBMP-8.4 chimeras, respectively [9,10]. Another study conducted on samples from Boliv-
ian immigrants living in Barcelona/Spain showed a sensitivity of 99.4% for IBMP-8.1 and
99.1% for IBMP-8.4 [24]. It is important to note that TcV is the most frequent DTU found in
Bolivia [4] and in Bolivian immigrants living in Barcelona [25]. These discrepancies may
reflect weaker adaptive immune responses to parasite antigens between endemic populations
[26].
Besides Bolivian samples, we also assayed samples from several endemic areas from Argen-
tina and Paraguay, geographic areas where prevail TcV/TcVI and TcV/TcIII genotypes,
respectively. However, no statistical difference was observed either with respect to sensitivity
and reactivity index when these samples were stratified according to the country of origin.
Although the number of Paraguayan samples is limited, we believe that the results can be
repeated using a larger number of samples. The number of inconclusive results, based on a
grey zone of 1.0 ± 10%, was higher for IBMP-8.1 compared to IBMP-8.4, which could be
attributed to the antigenic structure or amino acid composition. Approximately 13.3% of posi-
tive samples fell in the inconclusive zone when assayed with IBMP-8.1 while only 5.5% pre-
sented this same behavior with IBMP-8.4. With respect to negative samples, the number of
inconclusive results was low. In fact, four samples were inconclusive under IBMP-8.1 and only
one under IBMP-8.4 analysis. No sample from Paraguay felt inside the grey zone. Overall, no
significant coinciding inconclusive results were observed regarding IBMP-8.1 and IBMP8.4
assayed both positive and negative samples.
Other performance parameters were also considered here, such as positive and negative
likelihood ratios and diagnostic odds ratio. Positive LR was higher than 1,000 for both IBMP-
8.1 and IBMP-8.4 chimeras, indicating that a chronic Chagas disease carrier is approximately
1,000 times more likely to be diagnosed with this infection if evaluated with any of these anti-
gens. Chagas disease-negative samples returned LR values lower than 5.10−2 for IBMP-8.1 and
5.10−4 for IBMP-8.4. There is an agreement that negative LRs below 0.1 and positives LRs
above 10 contribute considerably to diagnosis [27]. DOR describes the probability of receiving
a positive result for a person with infection, as opposed to someone who is non-infected [28].
It is a universal performance parameter that summarizes the diagnostic test accuracy. Here, we
observed values greater than 24.103, which are in accordance with previous results [9,10].
Our findings showed a notable performance of IBMP-8.1 and -8.4 chimeras in diagnosing
chronic Chagas disease in individuals from endemic South American countries, confirming
our hypothesis that these antigens could be used in geographical areas where distinct T. cruzi
Diagnosis of Chagas disease using T. cruzi-chimeric antigens
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DTUs occur. The development of an accurate test for Chagas disease, regardless of T. cruzi-
intrinsic antigenic variability, is of extreme importance within public health’s perspective, by
simplifying diagnostic algorithms in relation to those presently used, making them more prac-
tical [29]. Furthermore, diagnostic costs may be reduced, due to the smaller number of samples
that would need to be re-assayed with different diagnostic methods, or by repeating the test on
another sample. However, further investigations are necessary to assess if these molecules
maintain their performance in diagnosing the infection in individuals living in North and
Central America or Northern region of South America, where Tc I prevails and Tc IV-infected
cases have been detected.
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